Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Pr... ( KING OF PRUSSIA Pa. Aug. 18 /- Em...)

HOME >> BIOLOGY >> TECHNOLOGY

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target

Date:8/18/2008

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostics that leverage its core CustomArray technology.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 888-293-1800.

This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more
'/>"/>

SOURCE Emerging Growth Equities, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
2. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
3. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
4. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
7. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
8. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference

Post Your Comments:

(Date:11/5/2009)... Transgenomic, Inc. (OTC ...sults for the quarter ended September 30, 2009. Th... tables that follow. ,, Third Quarter 2009 ,... $0.01 per share for the third quarter of 2009 as ...are for the third quarter of 2008. ,, Net sale...

(Date:11/5/2009)...ber 5, 2009 Senomyx, Inc...prietary taste receptor-based technologies to disc...ge, and ingredient supply industries, today provid...ts for the third quarter ended September 30, 2009.... of 2009, compared to $4.0 million for the third q...

(Date:11/5/2009)...Drug safety specialty firm BioSoteria announced th... earned the Certified Professional in Learning and...rican Society for Training and Development (ASTD) ...e than fifteen years of medical communications and...e for the development of the company,s online phar...

(Date:11/4/2009)...The Human Anthrax Vaccine Program must be stopped....re film "A Call to Arms:2009 Edition" an...Immunity: The Human Anthrax Vaccine Story" to...ger of top secret government science turned into f...ility to its victims. It is available for world-w...

[0] Transgenomic, Inc. Reports Third Quarter 2009 Results [0] SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS [0] BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification [0] Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing

...Presented at American Society for Metabolic and Ba...ting, SAN CLEMENTE, Calif., June 23 USGI Medical...presented clinical evidence showing,that its EndoS...s and,physicians to use an incisionless technique ...in patients who,ve regained weight after initial,s...

...PRING, Md. and SOUTH SAN FRANCISCO, Calif., June 2...d Actelion,Pharmaceuticals US, Inc. today announce...l PHA Award of Excellence in Pulmonary Arterial,Hy... $50,000, will be,awarded to an institution of Dr....llence in care for patients with PAH. The award, s...

...ion to enhance industry leader,s dermatological po...oratories Inc.,the world,s largest independent pha...oday announced it has signed a definitive merger a...ll acquire Barrier Therapeutics,Inc. ("Barrier The...ransaction, a tender offer followed by a merger of...

Other Biology Technology:Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass 2 Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care 2 Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care 3 Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care 4 Barrier Therapeutics to Merge Into Stiefel Laboratories 2 Barrier Therapeutics to Merge Into Stiefel Laboratories 3 Barrier Therapeutics to Merge Into Stiefel Laboratories 4 Barrier Therapeutics to Merge Into Stiefel Laboratories 5

Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care Barrier Therapeutics to Merge Into Stiefel Laboratories

(Date:11/5/2009)...of Biology Teachers (NABT) will recognize Leonard ...Naugatuck Valley Community College (NVCC) in Water...on Award during the NABT annual professional devel...n Denver, Colorado. , The Evolution Education Aw...ological Sciences,(AIBS) and Biological Sciences ...

(Date:11/5/2009)... been awarded a training grant in the amount of $2...its Integrative Graduation Education and Research ...grant to be awarded to Kent State. The grant, whic...stment Act of 2009, runs through 2014. , The gra...ent aquatic resource sensing (EARS). The purpose o...

(Date:11/4/2009)...tural science) , United States Using Less Wate...ay than it did 35 years ago, despite a 30 percent ...tly attributable to alternative cooling methods at...s. According to the latest USGS water use report, ... goes to cooling thermoelectric power plants. Irri...

Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2 Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2 USGS science picks 2 USGS science picks 3 USGS science picks 4 USGS science picks 5 USGS science picks 6 USGS science picks 7 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 1 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 2 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 3 Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 1 Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 2 Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 3 Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 4 While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 1 While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 2 While Some New Agents Will Achieve Strong Sales the Migraine Drug Market Will Decline 241 3 Billion by 2018 as Generic Erosion Takes Toll on Top Sel 53712 3

[0] Biologists, educators recognize excellence in evolution education [0] Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing [1] USGS science picks

...ids are synthetic hormones derived from the human ... been suspected in professional baseball and other...n endurance, is paramount. Power lifting is such a...act of anabolic steroid use on power lifters years...The researchers found that while physical traces o...

...udget was launched simultaneously by Global Carbon... Paris Observatory, and in the USA at Capitol Hill...l. , The Global Carbon Project posted the most re...to understanding the balance of carbon added to th...imate change. Despite the increasing international...

..., 2008 -Microbiologically contaminated water plagu...eri-urban populations in developing countries. Rou...nking water die each year from the consumption of ...5 years of age. , A new article published in Cu... instructions for constructing and using low-cost ...

Other Biology News:Anabolic steroids provide a competitive edge in power lifting years after doping has ended 2 Anabolic steroids provide a competitive edge in power lifting years after doping has ended 3 Growth in the global carbon budget 2

Anabolic steroids provide a competitive edge in power lifting years after doping has ended Growth in the global carbon budget Biological sand filters, a practical approach to combat poverty and inequality

...TI-RNase is a protein ribonuclease inhibitor that ...atic RNase A-type enzymes. No inhibition is seen w...is distinct from human placental ribonuclease inhi...h RNase and does not release active RNase in the a...

RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen

...e ChIP (Chemical Inkjet Printer) is a revolutionar...Protein Macroarray Analysis, developed in conjunct...ms. The strategy compliments established protocols...eins isoelectric point and apparent molecular weig...

...tural and Recombinant RNasin Ribonuclease Inhibito..., including the inhibition of eukaryotic RNases of...s inhibitory effect by noncovalently binding to RN...of RNasin Ribonuclease Inhibitor to RNase (e.g., R...

Biology Products:

ANTI-RNase from Ambion RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen Chemical Inkjet Printer from Shimadzu Biotech Recombinant RNasin^® Ribonuclease Inhibitor from Promega

Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Pr...( KING OF PRUSSIA Pa. Aug. 18 /- Em...)